Developer docs
API playgroundTry for free, no card

Search company profiles

Ziphius

Full company profile

uuid000273w

Namestring
Ziphius
Legal namestring
Ziphius NV
Websiteurl
ziphius.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Ziphius NV is a Belgium-based biopharmaceutical company founded in 2019, headquartered in Zwijnaarde (Ghent) with a US office opened in New York in May 2024. The company develops self-amplifying RNA (saRNA) vaccines and therapeutics built on two integrated proprietary platforms: a saRNA platform that encodes a viral RNA replicase enabling intracellular self-amplification and sustained protein expression at lower doses than conventional mRNA, and an in-house lipid nanoparticle (LNP) delivery library specifically engineered for saRNA encapsulation, stability, and biodegradability. The pipeline spans infectious disease prevention (Z009 Chlamydia vaccine in Discovery, Z010 Pan-Coronavirus vaccine in Preclinical, ZIP1642 dual-antigen COVID-19 vaccine in preclinical), rare genetic disease treatment (Z005 Cystic Fibrosis gene supplementation in Preclinical), and oncology (Z008, including personalized cancer vaccines and CAR-T applications in Preclinical).

The company is pre-commercial and generates no product revenue. Its planned monetization model relies on out-licensing and platform technology licensing to pharmaceutical partners, risk-sharing co-development arrangements, and ultimately product sales and royalties following regulatory approval. Go-to-market activity centers on B2B enterprise biopharma channels through strategic partnerships with contract manufacturers (Charles River for GMP plasmid DNA, UZ Ghent for first EU public-private GMP saRNA vaccine manufacturing), academic co-development with Ghent University and University of Antwerp, and investor/partner outreach at venues such as the J.P. Morgan Healthcare Conference. Target end-customers once commercial will be government public health agencies, healthcare systems, and pharmaceutical licensees across infectious disease, rare disease, and oncology segments. Strategic positioning is reinforced by an experienced leadership team including a former Janssen Vaccines R&D head as Chief Scientific Advisor, a Valneva/GSK Vaccines business development executive as Chief Business Officer, and VIB co-founder Jo Bury as Board Chairman.

Short descriptiontext

Ziphius is a Belgium-based biopharmaceutical company developing self-amplifying RNA vaccines and therapeutics delivered via proprietary lipid nanoparticles, with a pre-clinical pipeline spanning infectious diseases (chlamydia, pan-coronavirus, COVID-19), rare genetic disorders (cystic fibrosis), and oncology, targeting pharmaceutical partners and public health agencies through out-licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGhent, Belgium
HQ citystring
Ghent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
self-amplifying RNA vaccines, saRNA therapeutics, lipid nanoparticle delivery, infectious disease vaccines, rare disease therapeutics
Industry5 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Vaccines and Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Vaccine and Therapeutic Development
TypeLicensing Royalties
Description

Pre-commercial biopharmaceutical company developing saRNA-based vaccines and therapeutics. Revenue will be generated through product sales following regulatory approval, out-licensing deals, and strategic partnerships.

ziphius.org
2Platform Technology Licensing
TypeLicensing Royalties
Description

The company mentions seeking collaborations to explore its platform technologies in various disease areas through out-licensing or risk-sharing models.

ziphius.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ziphius Vaccines is a biopharmaceutical company developing self-amplifying RNA (saRNA) vaccines and therapeutics using its proprietary lipid nanoparticle (LNP) delivery platform. Its pipeline spans prophylactic vaccines for infectious diseases (chlamydia, pan-coronavirus, COVID-19), gene supplementation therapies for rare genetic disorders (cystic fibrosis), and next-generation oncology applications. Revenue is expected from out-licensing, co-development partnerships, and future product sales after regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Strong and lasting immune response with rapid, full clearance of virus demonstrated in non-human primate validation tests
+2 more records
Product overview1 text field

Ziphius is a biopharmaceutical company developing a portfolio of self-amplifying RNA (saRNA) vaccine and therapeutic programs built on two integrated technology platforms: the proprietary saRNA platform and the lipid nanoparticle (LNP) delivery platform. The company's pipeline includes four main programs: Z009 (Chlamydia vaccine in Discovery), Z010 (Pan Corona vaccine in Preclinical), Z005 (Cystic Fibrosis therapy in Preclinical), and Z008 (Oncology program in Preclinical), plus ZIP1642 (COVID-19 vaccine). The platform enables low-dose, high-efficacy treatments across infectious diseases, rare genetic disorders, and oncology by combining saRNA technology (which self-replicates within cells for amplified protein production) with LNP delivery systems designed for optimal stability and biodegradability.

Product and service7 records
1Z009 - Chlamydia Vaccine
CategoryInfectious Disease Vaccine
Description

Self-amplifying RNA vaccine candidate targeting Chlamydia trachomatis for prevention of human chlamydia infection; currently in Discovery phase and intended for public health use cases to reduce antibiotic reliance and outcomes such as infertility and ectopic pregnancy.

2Z010 - Pan Corona Vaccine
CategoryInfectious Disease Vaccine
Description

Self-amplifying RNA vaccine candidate targeting multiple coronavirus variants for broad coronavirus protection; currently in Preclinical phase.

3Z005 - Cystic Fibrosis Therapy
CategoryRare Disease Therapeutic
Description

Self-amplifying RNA-based gene supplementation therapy for cystic fibrosis, providing long-term expression of deficient or replacement proteins; currently in Preclinical phase.

4Z008 - Oncology Program
CategoryOncology Therapeutic
Description

Self-amplifying RNA-based therapeutic approach for next-generation oncology treatments, including personalized cancer vaccines and CAR-T cell therapies; currently in Preclinical phase.

5ZIP1642 - COVID-19 Vaccine
CategoryInfectious Disease Vaccine
Description

Dual-antigen self-amplifying RNA COVID-19 vaccine candidate encoding spike (S) and nucleocapsid (N) proteins; preclinical studies demonstrated protection against multiple SARS-CoV-2 variants including ancestral SARS-CoV-2 and the Beta B.1.351 variant.

6Self-Amplifying RNA (saRNA) Platform
CategoryTechnology Platform
Description

Proprietary self-amplifying RNA platform that enables RNA to self-replicate inside cells, amplifying protein production from a single molecule for higher and longer-lasting expression at lower doses than conventional mRNA; offered to partners via licensing and co-development.

7Lipid Nanoparticle (LNP) Delivery Platform
CategoryTechnology Platform
Description

In-house developed LNP library specifically designed for saRNA delivery, ensuring proper encapsulation, stability, and biodegradability; optimized for various administration routes across infectious disease vaccines, rare disease therapies, and oncology applications, and offered to partners via licensing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-07
Description

First EU public-private collaboration for production of saRNA-based vaccines under GMP standards. The partnership supports Belgium's Pandemic Preparedness strategy and involves scale-up and manufacturing of prophylactic self-amplifying RNA vaccines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-23
Description

Collaboration for early-stage clinical supply of plasmid DNA for drug substance manufacturing. Charles River leverages its industry-leading GMP and High Quality plasmid DNA production capabilities to support Ziphius's saRNA manufacturing program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-09
Description

Collaboration to research and develop a dynamic lipid library for optimized delivery systems of saRNA-based drugs and therapeutics. Leverages University of Antwerp's expertise in organic and medicinal chemistry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-06
Description

Collaboration resulting in publication of preclinical data from ZIP1642 COVID-19 vaccine candidate in Molecular Therapy journal. Partnership between Ziphius R&D team and Ghent University's Laboratory of Gene Therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-11
Description

Licensing agreement with UGhent as part of the business update, expanding Ziphius's intellectual property and technology access.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arcturus develops self-amplifying mRNA vaccines and therapeutics with proprietary LNP delivery, including a partnered saRNA COVID vaccine and CSL-collaboration influenza programs — the closest direct comparable to Ziphius's saRNA + LNP platform approach.

TypeDirect peer
Description

Replicate is a preclinical-stage biotech developing self-replicating RNA therapies for oncology and other indications, pursuing the same saRNA modality and at a similar stage and scale as Ziphius.

TypeBroad incumbent
Description

Moderna is the global leader in mRNA vaccines and therapeutics, with approved COVID and RSV products and an extensive pipeline. It anchors the broader mRNA modality in which Ziphius competes and against which any saRNA differentiation will be benchmarked.

TypeBroad incumbent
Description

BioNTech commercializes mRNA-based COVID vaccines and is expanding into oncology and infectious disease. As a large, profitable mRNA incumbent, it sets the competitive ceiling and partnership opportunity for saRNA-focused players like Ziphius.

TypeBroad incumbent
Description

CureVac is an mRNA technology company developing prophylactic vaccines, cancer therapies and protein therapeutics, with its own Lipid Nanoparticle delivery platform — a direct adjacent competitor in the broader mRNA/LNP vaccine category.

TypeBroad incumbent
Description

Sanofi acquired Translate Bio and is building an internal mRNA vaccine franchise; it is also a global vaccine incumbent. Sanofi represents both a potential acquirer/partner for Ziphius-style saRNA platforms and a major competitive threat in infectious disease vaccines.

TypeBroad incumbent
Description

CSL Seqirus partnered with Arcturus to advance a self-amplifying mRNA influenza vaccine and is a global vaccine distributor. It is a likely BD counterparty for any saRNA vaccine platform, including Ziphius's, and competes in the same prophylactic vaccine end-markets.

TypeEmerging player
Description

Kernal Biologics is an emerging mRNA therapeutics company developing selective translation technologies for oncology and infectious disease, with partial overlap in the mRNA platform space and a similar early-stage profile.

TypeOthers
Description

Acuitas is a leading LNP delivery technology provider that supplies lipid nanoparticles to multiple mRNA vaccine developers, including Pfizer-BioNTech for COVID. It is an enabling ecosystem peer to Ziphius's proprietary LNP library and a potential partnership or competitive reference.

TypeOthers
Description

Charité hosts major European vaccine development programs, including saRNA COVID vaccine work with CureVac. As an EU academic-public vaccine R&D counterpart, it is a relevant peer to Ziphius's Ghent/UZ Ghent academic-public model and a potential EU consortium partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ziphius

Biopharmaceutical Vaccines and Therapeuticsziphius.org

Ziphius is a Belgium-based biopharmaceutical company developing self-amplifying RNA vaccines and therapeutics delivered via proprietary lipid nanoparticles, with a pre-clinical pipeline spanning infectious diseases (chlamydia, pan-coronavirus, COVID-19), rare genetic disorders (cystic fibrosis), and oncology, targeting pharmaceutical partners and public health agencies through out-licensing.

What Ziphius does

Ziphius NV is a Belgium-based biopharmaceutical company founded in 2019, headquartered in Zwijnaarde (Ghent) with a US office opened in New York in May 2024. The company develops self-amplifying RNA (saRNA) vaccines and therapeutics built on two integrated proprietary platforms: a saRNA platform that encodes a viral RNA replicase enabling intracellular self-amplification and sustained protein expression at lower doses than conventional mRNA, and an in-house lipid nanoparticle (LNP) delivery library specifically engineered for saRNA encapsulation, stability, and biodegradability. The pipeline spans infectious disease prevention (Z009 Chlamydia vaccine in Discovery, Z010 Pan-Coronavirus vaccine in Preclinical, ZIP1642 dual-antigen COVID-19 vaccine in preclinical), rare genetic disease treatment (Z005 Cystic Fibrosis gene supplementation in Preclinical), and oncology (Z008, including personalized cancer vaccines and CAR-T applications in Preclinical).

The company is pre-commercial and generates no product revenue. Its planned monetization model relies on out-licensing and platform technology licensing to pharmaceutical partners, risk-sharing co-development arrangements, and ultimately product sales and royalties following regulatory approval. Go-to-market activity centers on B2B enterprise biopharma channels through strategic partnerships with contract manufacturers (Charles River for GMP plasmid DNA, UZ Ghent for first EU public-private GMP saRNA vaccine manufacturing), academic co-development with Ghent University and University of Antwerp, and investor/partner outreach at venues such as the J.P. Morgan Healthcare Conference. Target end-customers once commercial will be government public health agencies, healthcare systems, and pharmaceutical licensees across infectious disease, rare disease, and oncology segments. Strategic positioning is reinforced by an experienced leadership team including a former Janssen Vaccines R&D head as Chief Scientific Advisor, a Valneva/GSK Vaccines business development executive as Chief Business Officer, and VIB co-founder Jo Bury as Board Chairman.

Ziphius firmographics

Firmographics
Name
Ziphius
Legal name
Ziphius NV
Website
https://ziphius.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Ziphius is a Belgium-based biopharmaceutical company developing self-amplifying RNA vaccines and therapeutics delivered via proprietary lipid nanoparticles, with a pre-clinical pipeline spanning infectious diseases (chlamydia, pan-coronavirus, COVID-19), rare genetic disorders (cystic fibrosis), and oncology, targeting pharmaceutical partners and public health agencies through out-licensing.
Ownership category
akta.pro rank

Ziphius industry classification

Industry
Product category
Biopharmaceutical Vaccines and Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Self-amplifying RNA vaccines
  • SaRNA therapeutics
  • Lipid nanoparticle delivery
  • Infectious disease vaccines
  • Rare disease therapeutics

Where Ziphius is headquartered

Location

Headquarters

HQ city
Ghent
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

Ziphius business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Vaccine and Therapeutic Development: Pre-commercial biopharmaceutical company developing saRNA-based vaccines and therapeutics. Revenue will be generated through product sales following regulatory approval, out-licensing deals, and strategic partnerships.
  2. Platform Technology Licensing: The company mentions seeking collaborations to explore its platform technologies in various disease areas through out-licensing or risk-sharing models.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Ziphius product offering

Product offering

Core offering

Ziphius Vaccines is a biopharmaceutical company developing self-amplifying RNA (saRNA) vaccines and therapeutics using its proprietary lipid nanoparticle (LNP) delivery platform. Its pipeline spans prophylactic vaccines for infectious diseases (chlamydia, pan-coronavirus, COVID-19), gene supplementation therapies for rare genetic disorders (cystic fibrosis), and next-generation oncology applications. Revenue is expected from out-licensing, co-development partnerships, and future product sales after regulatory approval.

Product overview

Ziphius is a biopharmaceutical company developing a portfolio of self-amplifying RNA (saRNA) vaccine and therapeutic programs built on two integrated technology platforms: the proprietary saRNA platform and the lipid nanoparticle (LNP) delivery platform. The company's pipeline includes four main programs: Z009 (Chlamydia vaccine in Discovery), Z010 (Pan Corona vaccine in Preclinical), Z005 (Cystic Fibrosis therapy in Preclinical), and Z008 (Oncology program in Preclinical), plus ZIP1642 (COVID-19 vaccine). The platform enables low-dose, high-efficacy treatments across infectious diseases, rare genetic disorders, and oncology by combining saRNA technology (which self-replicates within cells for amplified protein production) with LNP delivery systems designed for optimal stability and biodegradability.

Differentiator

Problem solved

Functional benefit

Products and services

  • Z009 - Chlamydia Vaccine Self-amplifying RNA vaccine candidate targeting Chlamydia trachomatis for prevention of human chlamydia infection; currently in Discovery phase and intended for public health use cases to reduce antibiotic reliance and outcomes such as infertility and ectopic pregnancy.
  • Z010 - Pan Corona Vaccine Self-amplifying RNA vaccine candidate targeting multiple coronavirus variants for broad coronavirus protection; currently in Preclinical phase.
  • Z005 - Cystic Fibrosis Therapy Self-amplifying RNA-based gene supplementation therapy for cystic fibrosis, providing long-term expression of deficient or replacement proteins; currently in Preclinical phase.
  • Z008 - Oncology Program Self-amplifying RNA-based therapeutic approach for next-generation oncology treatments, including personalized cancer vaccines and CAR-T cell therapies; currently in Preclinical phase.
  • ZIP1642 - COVID-19 Vaccine Dual-antigen self-amplifying RNA COVID-19 vaccine candidate encoding spike (S) and nucleocapsid (N) proteins; preclinical studies demonstrated protection against multiple SARS-CoV-2 variants including ancestral SARS-CoV-2 and the Beta B.1.351 variant.
  • Self-Amplifying RNA (saRNA) Platform Proprietary self-amplifying RNA platform that enables RNA to self-replicate inside cells, amplifying protein production from a single molecule for higher and longer-lasting expression at lower doses than conventional mRNA; offered to partners via licensing and co-development.
  • Lipid Nanoparticle (LNP) Delivery Platform In-house developed LNP library specifically designed for saRNA delivery, ensuring proper encapsulation, stability, and biodegradability; optimized for various administration routes across infectious disease vaccines, rare disease therapies, and oncology applications, and offered to partners via licensing.

Quantifiable outcome

  • Strong and lasting immune response with rapid, full clearance of virus demonstrated in non-human primate validation tests
  • +2 more outcomes

Companies that use Ziphius

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Ziphius technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ziphius partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • UZ Ghent (University Hospital Ghent)coreStrategic or Co-development Partner · 7 October 2022First EU public-private collaboration for production of saRNA-based vaccines under GMP standards. The partnership supports Belgium's Pandemic Preparedness strategy and involves scale-up and manufacturing of prophylactic self-amplifying RNA vaccines.
  • Charles RivercoreStrategic or Co-development Partner · 23 June 2022Collaboration for early-stage clinical supply of plasmid DNA for drug substance manufacturing. Charles River leverages its industry-leading GMP and High Quality plasmid DNA production capabilities to support Ziphius's saRNA manufacturing program.
  • University of AntwerpcoreStrategic or Co-development Partner · 9 June 2022Collaboration to research and develop a dynamic lipid library for optimized delivery systems of saRNA-based drugs and therapeutics. Leverages University of Antwerp's expertise in organic and medicinal chemistry.
  • Ghent UniversitycoreStrategic or Co-development Partner · 6 May 2022Collaboration resulting in publication of preclinical data from ZIP1642 COVID-19 vaccine candidate in Molecular Therapy journal. Partnership between Ziphius R&D team and Ghent University's Laboratory of Gene Therapy.
  • UGhentcoreStrategic or Co-development Partner · 11 January 2021Licensing agreement with UGhent as part of the business update, expanding Ziphius's intellectual property and technology access.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Ziphius competitors and assessment

Company assessment

Direct peers

  • Arcturus Therapeutics: Arcturus develops self-amplifying mRNA vaccines and therapeutics with proprietary LNP delivery, including a partnered saRNA COVID vaccine and CSL-collaboration influenza programs — the closest direct comparable to Ziphius's saRNA + LNP platform approach.
  • Replicate Bioscience: Replicate is a preclinical-stage biotech developing self-replicating RNA therapies for oncology and other indications, pursuing the same saRNA modality and at a similar stage and scale as Ziphius.

Broad incumbents

  • Moderna: Moderna is the global leader in mRNA vaccines and therapeutics, with approved COVID and RSV products and an extensive pipeline. It anchors the broader mRNA modality in which Ziphius competes and against which any saRNA differentiation will be benchmarked.
  • BioNTech: BioNTech commercializes mRNA-based COVID vaccines and is expanding into oncology and infectious disease. As a large, profitable mRNA incumbent, it sets the competitive ceiling and partnership opportunity for saRNA-focused players like Ziphius.
  • CureVac: CureVac is an mRNA technology company developing prophylactic vaccines, cancer therapies and protein therapeutics, with its own Lipid Nanoparticle delivery platform — a direct adjacent competitor in the broader mRNA/LNP vaccine category.
  • Sanofi (Vaccines / Translate Bio): Sanofi acquired Translate Bio and is building an internal mRNA vaccine franchise; it is also a global vaccine incumbent. Sanofi represents both a potential acquirer/partner for Ziphius-style saRNA platforms and a major competitive threat in infectious disease vaccines.
  • CSL Seqirus: CSL Seqirus partnered with Arcturus to advance a self-amplifying mRNA influenza vaccine and is a global vaccine distributor. It is a likely BD counterparty for any saRNA vaccine platform, including Ziphius's, and competes in the same prophylactic vaccine end-markets.

Emerging players

  • Kernal Biologics: Kernal Biologics is an emerging mRNA therapeutics company developing selective translation technologies for oncology and infectious disease, with partial overlap in the mRNA platform space and a similar early-stage profile.

Others

  • Acuitas Therapeutics: Acuitas is a leading LNP delivery technology provider that supplies lipid nanoparticles to multiple mRNA vaccine developers, including Pfizer-BioNTech for COVID. It is an enabling ecosystem peer to Ziphius's proprietary LNP library and a potential partnership or competitive reference.
  • Charité — Universitätsmedizin Berlin (vaccine research): Charité hosts major European vaccine development programs, including saRNA COVID vaccine work with CureVac. As an EU academic-public vaccine R&D counterpart, it is a relevant peer to Ziphius's Ghent/UZ Ghent academic-public model and a potential EU consortium partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ziphius social profiles

Digital presence

Ziphius financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ziphius leadership team

Management profile

Number of profiles

Profiles14 records

Ziphius funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ziphius M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ziphius

What does Ziphius do?

Ziphius Vaccines is a biopharmaceutical company developing self-amplifying RNA (saRNA) vaccines and therapeutics using its proprietary lipid nanoparticle (LNP) delivery platform. Its pipeline spans prophylactic vaccines for infectious diseases (chlamydia, pan-coronavirus, COVID-19), gene supplementation therapies for rare genetic disorders (cystic fibrosis), and next-generation oncology applications. Revenue is expected from out-licensing, co-development partnerships, and future product sales after regulatory approval.

Is Ziphius a public or private company?

Ziphius is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ziphius founded?

Ziphius was founded in 2019. It employs 11 to 50 people.

Where is Ziphius based?

Ziphius is headquartered in Ghent, Belgium, in the Europe region.

How does Ziphius make money?

Two revenue lines are on record. Vaccine and Therapeutic Development is the primary driver. The others are platform Technology Licensing.

Who are Ziphius's main competitors?

Direct peers on record are Arcturus Therapeutics and Replicate Bioscience. Broad incumbents are Moderna, BioNTech, CureVac, Sanofi (Vaccines / Translate Bio) and CSL Seqirus. Kernal Biologics is listed as an emerging player. Others are Acuitas Therapeutics and Charité — Universitätsmedizin Berlin (vaccine research).

Does Ziphius have an API?

No public API is recorded for Ziphius.

What industry is Ziphius in?

Ziphius's product category is Biopharmaceutical Vaccines and Therapeutics. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAKAE, Plasmid DNA & mRNA Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireZiphius, une société de biotechnologie de premier plan spécialisée dans l’ARN auto-amplificateur, annonce aujourd’hui la nomination de M. Antoon Loomans au sein de son conseil d’administrationZiphius named Antoon Loomans to its board, effective immediately, to lead US commercial development. The company is also raising €30 million to fund its Chlamydia vaccine program through Phase I trials. Loomans brings 30 years of vaccine industry experience.FinancialContent Business PageZiphius, a leading saRNA biotech, today announces the appointment of Mr. Antoon Loomans to its Board of DirectorsZiphius appointed Antoon Loomans to its board, effective immediately, to lead U.S. business development and partnerships. The company is advancing its Chlamydia trachomatis vaccine program and a €30 million financing round. Loomans previously led business development at GSK Vaccines and Vaccine Company.GlobeNewswireZiphius, a leading saRNA biotech, today announces the appointment of Mr. Antoon Loomans to its Board of DirectorsZiphius appointed Antoon Loomans to its board, effective immediately, to lead U.S. business development and partnerships. The company is advancing its Chlamydia trachomatis vaccine program and a €30 million financing round. Loomans previously led business development at GSK Vaccines and Vaccine Company.BioSpaceCharles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based VaccineCharles River Laboratories and Ziphius Vaccines announced an agreement to manufacture plasmid DNA starting materials for clinical-stage research. The collaboration aims to deliver early-stage clinical supply, leveraging Charles River's GMP and high-quality plasmid production capabilities. The partnership supports Ziphius's saRNA vaccine platform development.